Clinical Trials
45 trialsNCT03610022 2026-05-19
OPTIVISMO-1
University Hospital, Bordeaux
Phase 4 Completed
NCT00833417 2026-05-11
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma
Genentech, Inc.
Phase 2 Completed
NCT00959647 2026-05-08
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Genentech, Inc.
Phase 2 Completed
NCT02667574 2026-04-22
VISMONEO
University Hospital, Lille
Phase 2 Completed
NCT03498521 2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2 Completed
NCT01064622 2024-11-19
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02091141 2024-07-23
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 2 Completed
NCT02073838 2023-09-29
Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML
Jewish General Hospital
Phase 2 Completed
NCT03158389 2023-09-28
N²M²
University Hospital Heidelberg
Phase 1/2 Completed
NCT03035188 2022-02-11
NICCI
SRH Wald-Klinikum Gera GmbH
Phase 2 Completed
NCT02436408 2021-10-28
VISORB
University of Michigan Rogel Cancer Center
Phase 4 Completed
NCT03052478 2021-06-08
Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression
Samsung Medical Center
Phase 2 Completed
NCT01835626 2021-05-03
Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
University of California, San Francisco
Phase 2 Completed
NCT02366312 2021-02-18
KCOT
NYU College of Dentistry
Phase 2 Completed
NCT00957229 2021-01-11
GDC-0449
UCSF Benioff Children's Hospital Oakland
Phase 2 Completed
NCT00887159 2021-01-05
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage
National Cancer Institute (NCI)
Phase 2 Completed
NCT01556009 2020-11-02
Vismodegib
UCSF Benioff Children's Hospital Oakland
Phase 2 Completed
NCT02371967 2020-10-09
ROSETT
Hoffmann-La Roche
Completed
NCT01367665 2019-06-06
STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
Hoffmann-La Roche
Phase 2 Completed
NCT01700049 2019-05-23
Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes
Mayo Clinic
Phase 2 Completed
NCT02674009 2019-05-13
NIELS
Hoffmann-La Roche
Completed
NCT01088815 2019-04-26
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01537107 2019-04-08
Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery
Mayo Clinic
Phase 1 Completed
NCT02690948 2019-03-08
Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer
Stanford University
Phase 1/2 Completed
NCT01154452 2018-08-15
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT02115828 2018-07-20
A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase EARLY_PHASE1 Completed
NCT02639117 2018-07-18
PDT-Vismo
University of Arizona
Phase 1 Completed
NCT01631331 2017-12-08
Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)
Stanford University
Phase EARLY_PHASE1 Completed
NCT01815840 2017-09-28
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
Hoffmann-La Roche
Phase 2 Completed
NCT00980343 2017-08-16
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01195415 2017-08-07
Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00968981 2017-07-11
A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
Genentech, Inc.
Phase 1 Completed
NCT00636610 2017-06-08
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer
Genentech, Inc.
Phase 2 Completed
NCT00739661 2017-06-08
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission
Genentech, Inc.
Phase 2 Completed
NCT01174264 2017-05-19
Evaluation of Food Effect on Pharmacokinetics of Vismodegib
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01546519 2016-05-23
A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function
Genentech, Inc.
Phase 1 Completed
NCT00939484 2016-02-25
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00982592 2016-01-25
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01239316 2016-01-14
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00607724 2015-10-08
GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT01209143 2015-06-29
A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
Genentech, Inc.
Phase 1 Completed
NCT01330173 2014-12-23
Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Completed
NCT01543581 2014-09-26
Erivedge
Loma Linda University
Phase 2 Completed
NCT01201915 2014-06-24
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
Genentech, Inc.
Phase 2 Completed
NCT00822458 2014-04-02
GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment
National Cancer Institute (NCI)
Phase 1 Completed